CD274 and neoplasm: In Enz resistance, the concurrent application of histone modification modulators and immune checkpoint inhibitors (such as anti-PD-1/PD-L1 antibodies) may bolster the immune system's surveillance and cytotoxic capabilities against tumor cells 86.